Synta Pharmaceuticals news from FierceBiotech
NewsSynta outlines cash flow from Glaxo pact
Synta Pharmaceuticals' new, $1 billion pact with GlaxoSmithKline for the cancer drug elesclomol (code named Read more...
Synta scores $1.1B deal with GSK
Synta Pharmaceuticals broke the billion-dollar mark in its new licensing deal with GlaxoSmithKline. Glaxo has agreed to pay Synta $80 million up front and up to $1.1 billion in total for the deal Read more...
Synta therapy slows spread of melanoma
Lexington, MA-based Synta Pharmaceuticals caused quite a stir with a recent presentation on an early-stage cancer therapy that slowed the spread of aggressive skin cancer. In the Phase IIb trial, Read more...
ALSO NOTED: MediGene begins trial in RA; Study finds women shortchanged on chemotherapy;and much more...> Germany's MediGene has begun mid-stage trials of the rheumatoid arthritis drug RhuDex. Report > Women with little education or low incomes are more likely to get insufficient levels of chemotherapy when being treated for breast cancer, which translates into higher mortality rates for the group. Researchers add that as many as half of all women being given chemotherapy are getting … Read more...Synta files $115M IPOPerhaps buoyed by a string of positive data, 2004 Fierce 15 winner Synta Pharmaceuticals is filing a $115 million IPO despite the risky biotech IPO climate. The Lexington, MA biotech has yet to determine the number of shares to be offered and the price range for the offering. Earlier this month the FDA granted Synta fast-track status for its lead oncology drug candidate, … Read more...SPOTLIGHT: Synta gets fast track for cancer therapy
Press Release: Synta Pharmaceuticals gets FDA Fast Track Designation for STA-4783Synta Pharmaceuticals gets FDA Fast Track Designation for STA-4783 Read more...SPOTLIGHT: Synta trial hits endpointSynta Pharmaceuticals says that a Phase IIb clinical trial of STA-4783 doubled the progression free survival time of volunteers with metastatic melanoma in the study, hitting the study's primary endpoint for statistical significance. Median PFS for patients receiving STA-4783 plus paclitaxel was 112 days versus 56 days for those receiving paclitaxel alone. Report | Press ReleasesPRESS RELEASE: Synta Receives $80 Million Upfront Payment from GlaxoSmithKline Synta Receives $80 Million Upfront Payment from GlaxoSmithKline Payment Received Following Expiration of Hart-Scott-Rodino Waiting Period LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Read more... PRESS RELEASE: Synta Pharmaceuticals Reports Third-Quarter 2007 Financial Results Synta Pharmaceuticals Reports Third-Quarter 2007 Financial Results LEXINGTON, Mass. -- Synta Pharmaceuticals, a biopharmaceutical company focused on discovering, developing, and commercializing Read more... PRESS RELEASE: New type of drug shows promise in attacking melanoma in an innovative way New type of drug shows promise in attacking melanoma in an innovative way Barcelona, Spain: An experimental drug that attacks cancer in an entirely new way has shown promise in treating advanced Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets